Yes, first they have to get the safety data out of
Post# of 144932
![Avatar](/images/ProfileImages/947101588_48586_morph.jpg)
Also if TNBC numbers are good and leronlimab is approved for combo, it is not uncommon for off-label in cancer--I believe 40% of prescribed drugs in oncology is off-label. It is usually though using one cancer drug for another cancer, but I posted here people had insurance approve maraviroc for cancer treatment based on their phase 2 results.
If leronlimab is approved for tnbc, then the off-label use will skyrocket in other cancers in my opinion, even before moa is approved.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)